Table 1.

APSN and APS featuresa

Groupn (%)Exclusionn (%)OR (95% CI)P
a OR, odds ratio; CI, confidence interval; APSN, antiphospholipid syndrome nephropathy; APS, antiphospholipid syndrome; LA, lupus anticoagulant; ACL, anticardiolipin antibodies; APL, total cases having either LA and/or aCL.
APSN
 APS15 of 24 (63%)non-APS18 of 83 (22%)6 (2.4 to 15.2)0.0001
 LA20 of 33 (61%)non-LA16 of 77 (21%)5.9 (2.5 to 13.8)0.0001
 ACL21 of 65 (32%)non-aCL8 of 25 (32%)NS0.98
 APL28 of 76 (37%)non-APL3 of 20 (15%)NS0.063
Chronic APSN
 APS11 of 24 (46%)non-APS15 of 83 (18%)3.8 (1.5 to 9.9)0.005
 LA16 of 33 (48%)non-LA11 of 77 (14%)5.7 (2.3 to 13.8)0.0001
 ACL16 of 65 (25%)non-aCL6 of 25 (24%)NS0.95
 APL22 of 76 (29%)non-APL2 of 20 (10%)NS0.082
Acute APSN
 APS8 of 24 (33%)non-APS10 of 83 (11%)3.7 (1.2 to 10.3)0.026
 LA11 of 33 (33%)non-LA9 of 77 (12%)3.8 (1.4 to 10)0.007
 ACL11 of 65 (17%)non-aCL5 of 25 (20%)NS0.763
 APL15 of 76 (20%)non-APL2 of 20 (15%)NS0.5
FCA
 APS10 of 24 (42%)non-APS6 of 86 (7%)9.2 (3.2 to 26.1)0.0002
 LA12 of 33 (36%)non-LA5 of 77 (6%)8.2 (2.9 to 23.4)0.0001
 ACL11 of 65 (17%)non-aCL4 of 25 (16%)NS0.99
 APL16 of 76 (21%)non-APL0 of 20 (0%)NS0.02